Iovance Biotherapeutics Inc at JMP Securities Hematology and Oncology Forum (Virtual) Transcript
Well good afternoon, everyone. It's my pleasure to introduce Iovance Biotherapeutics, Maria Fardis, President and CEO. Maria, thanks for joining us here. And as I've been kind of starting off all the conversations with our cell therapy companies, we don't know exactly who's in the audience, whether they're familiar with Iovance, whether they're not, so would love to take maybe a couple of minutes, if you could give us an overview of Iovance.
Yes, absolutely. And thank you for the invitation, Reni. This is great to be here.
Iovance is a cell therapy company for administering a product called tumor-infiltrating lymphocytes, or TIL, for solid tumors. The original concept for the product came from National Cancer Institute, or NCI. We took a license in 2011. We have developed a product into now a commercial-ready product. The manufacturing process initially was around 6 to 7 weeks, and we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
